MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
common stock pursuant...
$14,762K
Proceeds from exercise of
stock options
$774K
Proceeds from issuance of
common stock under...
$23K
Net cash provided by
financing activities
$14,587K
Canceled cashflow
$972K
(decrease) increase in
cash, cash...
-$118,591K
Canceled cashflow
$14,587K
Maturities of investments
$32,000K
Stock-based compensation
$13,621K
Change in fair value of
derivative liability
-$9,520K
Accrued expenses and
other liabilities,...
$6,662K
Depreciation and
amortization
$344K
Deferred taxes
$165K
Cash paid related to
withholding shares to...
$510K
Transaction costs paid
pursuant to atm program
$462K
Net cash (used in)
provided by investing...
-$81,720K
Net cash used in
operating activities
-$51,458K
Canceled cashflow
$32,000K
Canceled cashflow
$30,312K
Purchase of investments
$113,720K
Net loss
-$78,259K
Prepaid expenses and
other assets
$2,588K
Accretion of
available-for-sale investments,...
$690K
Accounts payable
-$146K
Lease liability, net
-$87K
Back
Back
Cash Flow
source: myfinsight.com
Avalo Therapeutics, Inc. (AVTX)
Avalo Therapeutics, Inc. (AVTX)